W. C. Willett, B. Rockhill, and S. E. Hankinson, Epidemiology and nongenetic causes of breast cancer, Disease of the Breast, pp.175-220, 2000.

J. Bonneterre, H. Roche, and P. Kerbrat, Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial, J Clin Oncol, vol.23, pp.2686-2693, 2005.

B. Chevallier, P. Fumoleau, and P. Kerbrat, Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer, J Clin Oncol, vol.13, pp.314-322, 1995.

P. M. Ravdin, H. A. Burris, . Iii, and G. Cook, Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer, J Clin Oncol, vol.13, pp.2879-2885, 1995.

V. Valero, F. A. Holmes, and R. S. Walters, Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclineresistant metastatic breast cancer, J Clin Oncol, vol.13, pp.2886-2894, 1995.

I. C. Henderson, D. A. Berry, and G. D. Demetri, Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol, vol.21, pp.976-983, 2003.

E. P. Mamounas, J. Bryant, and B. Lembersky, Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28, J Clin Oncol, vol.23, pp.3686-3696, 2005.

M. Martin, T. Pienkowski, and J. Mackey, Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, vol.352, pp.2302-2313, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-02273164

P. Marino, Measuring the cost of chemotherapy is important, but it is not enough, Ann Oncol, vol.19, pp.409-410, 2008.

, Sensitivity analysis showing the impact of the decrease in the cost of docetaxel on the estimates and associated confidence intervals. Graph shows ICERs relative to a variation in the cost of docetaxel. The dashed line is relative to ICER point estimates. The figures represent the value of the upper bound of the ICER confidence intervals

H. Roche, P. Fumoleau, and M. Spielmann, Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial, J Clin Oncol, vol.24, pp.5664-5671, 2006.

A. Willan and A. Briggs, The Statistical Analysis of Cost-effectiveness Data, 2006.

T. O. Tengs and A. Wallace, One thousand health-related quality-of-life estimates, Med Care, vol.38, pp.583-637, 2000.

V. Cocquyt, K. Moeremans, and L. Annemans, Long-term medical costs of postmenopausal breast cancer therapy, Ann Oncol, vol.14, pp.1057-1063, 2003.

C. De-peretti and C. Siani, Decision-making with the incremental cost-effectiveness ratio under uncertainty, Health Syst Sci, vol.9, issue.1-2, pp.111-145, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01510981

C. Siani and C. De-peretti, Fieller's method performance in problematic cases for decision-making, Health Syst Sci, vol.9, issue.1-2, pp.205-226, 2006.

N. Devlin and D. Parkin, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Econ, vol.13, pp.437-452, 2004.

H. G. Eichler, S. X. Kong, and W. C. Gerth, Use of cost-effectiveness analysis in healthcare resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?, Value Health, vol.7, pp.518-528, 2004.

R. A. Hirth, M. E. Chernew, and E. Miller, Willingness to pay for a quality-adjusted life year: in search of a standard, Med Decis Making, vol.20, pp.332-342, 2000.

J. Raftery, NICE: faster access to modern treatments? Analysis of guidance on health technologies, BMJ, vol.323, pp.1300-1303, 2001.

A. M. Garber, Advances in cost-effectiveness analysis of health interventions, Handbook of Health Economics, vol.1, pp.181-221, 2000.

D. K. Owens, Interpretation of cost-effectiveness analyses, J Gen Intern Med, vol.13, pp.716-717, 1998.

M. Weinstein, Valuing Health Care: Costs, Benefits & Effectiveness of Pharmaceuticals and Other Medical Technologies, pp.77-97, 1995.

H. J. Au, K. Golmohammadi, and T. Younis, Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects, Breast Cancer Res Treat, 2009.

S. E. Wolowacz, D. A. Cameron, H. C. Tate, and A. Bagust, Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis, J Clin Oncol, vol.26, pp.925-933, 2008.

T. Younis, D. Rayson, M. Sellon, and C. Skedgel, Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100, Breast Cancer Res Treat, vol.111, pp.261-267, 2008.

S. Ward, E. Simpson, and S. Davis, Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation, Health Technol Assess, vol.11, pp.1-144, 2007.

M. S. Pharmacogenomics, Ann Oncol, 2007.